BioPharmSignal logoBioPharmSignal

Biotech News

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Fennec Pharmaceuticals Inc. (FENC)Fennec Pharmaceuticals Inc.2026-06-25 13:46 ESTEarnings

~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK ® in Adolescent and Young Adult

Open original release

Related news

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

FENCFennec Pharmaceuticals Inc.2026-06-25 13:46 EST

Fennec Pharmaceuticals Announces Settlement Agreement Resolving PEDMARK Patent Litigation

View all latest news

Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Announces Results of Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

FENCFennec Pharmaceuticals Inc.2026-06-26 07:27 EST

Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States